Injectable HIV prevention study in Cape Town
Treatments studied
Part of Infections clinical trials.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 35 years old
- You must weigh more than 35 kg (about 77 lbs)
- You must be HIV-negative at the start of the study
- You must be sexually active (had at least 2 sexual encounters in the last 3 months)
- You must live, work, or study in the Cape Town area and be able to attend study visits
- You cannot have certain medical conditions or take medications that interfere with the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different ways to take HIV prevention medicine (PrEP) for men who travel for work. It compares daily pills, pills taken only around sex, and a long-acting injection to see which works best for mobile men in sub-Saharan Africa.
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.